Combination with BCG induction and maintenance therapy for high-risk non-muscle invasive bladder cancer.

For over 50 years, intravesical Bacillus Calmette-Guérin (BCG) has been the standard of care for high-risk non-muscle invasive bladder cancer (HR-NMIBC)1. Historically, patients with HR-NMIBC treated with BCG have a 50 and 76% chance of disease-free survival at three years depending on the amount of maintenance BCG given2. Recurrent disease often requires more aggressive treatment, such as bladder instillation of…